Rare disease prevention and treatment: the need for a level playing field.
Pharmacogenomics
; 19(3): 243-247, 2018 02.
Article
in En
| MEDLINE
| ID: mdl-29327657
ABSTRACT
Pharmacogenetic tests are being used increasingly to prevent rare and potentially life-threatening adverse drug reactions. For many tests, however, cost-effectiveness is hard to demonstrate, and with the exception of a few cases, widespread implementation remains a distant prospect. Many orphan drugs for rare diseases are also not cost effective but are nonetheless normally reimbursed. In this article, we argue that the health technology assessment of pharmacogenetic tests aimed to prevent rare but severe adverse drug reactions should be on a level playing field with orphan drugs. This is supported by a number of arguments, concerning the severity, rarity and iatrogenic nature of adverse drug reactions, the distribution of benefits and costs and societal preference towards prevention over treatment.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rare Diseases
/
Drug-Related Side Effects and Adverse Reactions
/
Pharmacogenomic Testing
Type of study:
Health_technology_assessment
Limits:
Humans
Language:
En
Journal:
Pharmacogenomics
Journal subject:
FARMACOLOGIA
/
GENETICA MEDICA
Year:
2018
Document type:
Article
Affiliation country: